» Articles » PMID: 39545339

Evolving Molecular Classification of Aggressive B-cell Lymphoma

Overview
Journal Histopathology
Date 2024 Nov 15
PMID 39545339
Authors
Affiliations
Soon will be listed here.
Abstract

This review aims to provide an overview of the latest developments in the classification and molecular understanding of aggressive B-cell lymphomas, specifically focusing on diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL). Advances in molecular techniques have led to novel ways to classify these lymphomas based on clinical, histological, transcriptional, and genetic properties. While these methods have predominantly focused on the malignant compartment, recent studies emphasize the value of profiling the tumour microenvironment for a more comprehensive disease classification. Additionally, the integration of liquid biopsies represents a promising advancement, offering less invasive and dynamic insights into tumour characteristics and treatment response. Although molecular profiles are not yet routinely used to guide therapy, emerging data highlight their potential to predict responses to novel treatments. It is our belief that integrating molecular profiling and liquid biopsies into clinical practice and research now will pave the way for more personalized and effective therapies in the future.

References
1.
Alaggio R, Amador C, Anagnostopoulos I, Attygalle A, de Oliveira Araujo I, Berti E . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7):1720-1748. PMC: 9214472. DOI: 10.1038/s41375-022-01620-2. View

2.
Ennishi D, Mottok A, Ben-Neriah S, Shulha H, Farinha P, Chan F . Genetic profiling of and in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. Blood. 2017; 129(20):2760-2770. DOI: 10.1182/blood-2016-11-747022. View

3.
Wright G, Huang D, Phelan J, Coulibaly Z, Roulland S, Young R . A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell. 2020; 37(4):551-568.e14. PMC: 8459709. DOI: 10.1016/j.ccell.2020.03.015. View

4.
Wilson W, Wright G, Huang D, Hodkinson B, Balasubramanian S, Fan Y . Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 2021; 39(12):1643-1653.e3. PMC: 8722194. DOI: 10.1016/j.ccell.2021.10.006. View

5.
Sworder B, Kurtz D, Alig S, Frank M, Shukla N, Garofalo A . Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell. 2022; 41(1):210-225.e5. PMC: 10010070. DOI: 10.1016/j.ccell.2022.12.005. View